Compare Novavax Inc (NVAX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.85 (market cap $21.89B). The key difference: Consumer Discretionary Select Sector SPDR Fund is far larger — about 12× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| NVAX | XLY | |
|---|---|---|
Market Cap | $1.82B | $21.89B |
Volume | 6,198,505 | 5,690,342 |
Sector | Health | — |
52-Week High | $12.56 | $124.52 |
52-Week Low | $6.22 | $105.64 |
Typical Hold Time | 59 Days | 114 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
XLY trades at $111.70, up 0.31% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF has underperformed the consumer staples sector in 2026, declining over 7% while XLP gained 6.6%. Analyst consensus remains unanimously bullish with 100% buy ratings, though technical indicators show RSI_6 at 82.40 suggesting potential overbought conditions near-term.
XLY faces headwinds from consumer spending shifts toward value and persistent inflation pressures, but potential catalysts include holiday retail growth projections and the 'funflation' trend. The ETF's heavy concentration in top holdings creates both opportunity and risk, with support at $110-$111 and resistance at $112-$113 defining near-term price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
